Accepting PhD Students

PhD projects

Douglas Ward’s research applies genomic and proteomic approaches to discover biomarkers by analysing carefully collected clinical samples. This work capitalises on the advanced mass spectrometry equipment provided by Birmingham Science City, the large patient base in the West Midlands, and local scientific, clinical, bioinformatic and statistical expertise. Most of his work focuses on identifying novel tumour markers for lung, liver, GI tract and bladder cancers. He also uses proteomics to study α-antitrypsin deficiency and organ transplantation. In addition to biomarker discovery, Dr Ward is also interested in using mass spectrometry to assay biomarkers where immunoassays are not suitable, and in the downstream validation of promising candidates.

20002023

Research activity per year

Filter
Patent

Search results

  • 2016

    Bladder cancer prognosis

    Bryan, R. & Ward, D., 2 Jun 2016, IPC No. G01N 33/574 (2006.01), G01N 33/68 (2006.01), Patent No. WO/2016/083832, Priority date 28 Nov 2014, Priority No. US 62/085,433

    Research output: Patent

    Open Access
    File
    4 Citations (Scopus)
    62 Downloads (Pure)